Researchers have revealed that a candidate vaccine against the joint disease chikungunya showed promise by provoking an immune response in human trials. The trial drug is made with nanoparticles that resemble a West African strain of the virus, which causes high fever and intensely painful arthritis, said a study in The Lancet medical journal. These virus-like particles (VLPs) are meant to mimic the immune-stimulating effects of the actual virus particles, ...
via Medindia Health News More READ
via Medindia Health News More READ
No comments:
Post a Comment